Illumina Accelerator has chosen five start-ups for its seventh class. Applications for the accelerator’s eighth cohort are open now and are due by May 1. The new cohort are focused on skin microbial therapeutics, fertility science, chronic disease alleviation, post-traumatic stress disorder treatment, biopharmaceutical services and clinical research services. “Each of the startups is working to solve a problem that we all face in our daily lives,” said Dr. David L. Anderson, CEO of Illumina. The companies will also gain access to Illumina spin-out Helix and its experts in bioinformatics, applied genomics, product development and consumer marketing.
Illumina Accelerator has chosen five start-ups for its seventh class. The new cohort are focused on skin microbial therapeutics, fertility science, chronic disease alleviation, post-traumatic stress disorder treatment, biopharmaceutical services and clinical research services. “Each of the startups is working to solve a problem that we all face in our daily lives,” said Dr. David L. Anderson, CEO of Illumina. The companies will also gain access to Illumina spin-out Helix and its experts in bioinformatics, applied genomics, product development and consumer marketing.